A new kind of HIV prevention is making it easier for those at risk to stay protected, thanks to a twice-yearly injection now ...

Experts are celebrating a breakthrough in HIV prevention. Doctors say it could mean we're one step closer to eradicating the ...

In his rescissions request to Congress last month, President Donald Trump asked that the hundreds of millions dollars budgeted for the President's Emergency Plans for AIDS Relief, or PEPFAR, be ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that new data from its research ...

The world’s only twice-a-year shot to prevent HIV could stop transmission — if people can get it It’s the first step in an anticipated global rollout that could protect millions.

A drug called lenacapavir, administered in two injections a year, offers protection from HIV comparable to daily pills. One looming question: Will it be affordable for lower resource countries?

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A once-daily pill named PrEP, or pre-exposure prophylaxis, has been a ...

After years of stagnation, Gilead is betting that a twice-yearly HIV shot can restart its growth engine.

May 30 (Reuters) - Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in low-income countries if it wins U.S. approval despite funding ...

A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.